Stock info Amgen | Filter  Basic-Info

Amgen

The company's head quarter is located in Thousand Oaks. The company mostly operates in the biotech sector. Robert A. Bradway is operating by ' CEO. Michael A. Kelly runs the company as a CFO. The global biotech companies gained around 59 percent over the last 10 years. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-2016) there is a minus of 59 percent.

The past year yielded positive returns for Amgen investors

The stock lost over the past 12 months at around 7 percent. Over the period from December 2011 till December 2016 the stock rose on average 132 percent. Amgen's revenues between 2011 and 2015 were very volatile through the time and moved between 17,27 billion dollars and 21,66 billion dollars. Amgen's net incomes between 2011 and 2015 were very volatile and moved between 3,68 billion dollars and 6,94 billion dollars.

Over the past 5 years the American company paid out dividends. Over the past 5 years Amgen's dividend yield was at around 9,48 percent per year.

Amgen had about 17,9 thousand employees at the end of 2015.

Amgen' balance mostly financed with equity

At the end of 2015 the American company had a balance sheet of around 71,58 billion dollars. Of the total balance sheet 43,49 billion dollars (60,76 percent) was financed by debt. Last year the biotech company's price/earnings-ratio (PE) was around 17. So the investors valued the stock at 17 times 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

At the end of 2015 the American company's market capitalization equaled around 119,11 billion dollars. At the end of 2015 the American company had around 754 million stocks listed.

At this page you find all Amgen's financial reports. More information about Amgen can be found it's website. .